Search Results 7991-8000 of 33422 for oral
Participants who are able to switch to low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) prior to date of registration (and plan to ...
Stable dose (defined as no change in prescription for at least 4 weeks prior to Day 1) of NSAIDs, HCQ, MTX and/or oral corticosteroids is permitted during ...
Able to swallow oral formulation of the study agent; Hemoglobin >= 9 g/dL; Platelet count >= 75,000/mm^3; Creatinine =< 1.5 x upper limits of normal (ULN) ...
Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation ...
... oral, implantable, or injectable route of administration;; intrauterine device (IUD);; intrauterine hormone-releasing system (IUS);; bilateral tubal occlusion ...
Yet, from time to time, we hear from concerned consumers, our patients and employees, or the media about materials they see in the marketplace where a non-Mayo ...
Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas. Obstetrics & Gynecology. 2023; doi:10.1097/AOG.0000000000005145 ...
... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...
... oral therapy (10% of patients in the study were also taking ezetimibe). The median LDL cholesterol was 105 mg/dL in both groups. At the termination of the ...
Dr. Donald Hensrud says alcohol is the third-leading preventable cause of cancer in the U.S., behind tobacco use and obesity.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.